Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease

Journal of Hypertension

Volumn 30, Issue 11, 2012, Pages 2192-2201

  Naito, Yoshiro ^a   Fujii, Aya ^a   Sawada, Hisashi ^a   Hirotani, Shinichi ^a   Iwasaku, Toshihiro ^a   Eguchi, Akiyo ^a   Ohyanagi, Mitsumasa ^a   Tsujino, Takeshi ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

chronic kidney disease; hypertension; iron; mineralocorticoid receptor; transferrin receptor 1

Indexed keywords

CARRIER PROTEIN; CD68 ANTIGEN; CD71 ANTIGEN; COLLAGEN TYPE 3; IRON; MINERALOCORTICOID RECEPTOR; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULOSCLEROSIS; HYPERTENSION; INTERSTITIAL NEPHRITIS; IRON RESTRICTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY STRUCTURE; KIDNEY TUBULE; MALE; NEPHRECTOMY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SIGNAL TRANSDUCTION; URINARY EXCRETION;

EID: 84867744655     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283581a64     Document Type: Article

References (24)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitaliz-ation. N Engl J Med 2004; 351:1296-1305.
2. Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal disease. Am J Kidney Dis 1992; 20:580-584.
3. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16:3631-3641.
4. Nankivell BJ, Chen J, Boadle RA, Harris DC. The role of tubular iron accumulation in the remnant kidney. J Am Soc Nephrol 1994; 4:1598-1607.
5. Harris DC, Tay C, Nankivell BJ. Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin Exp Pharmacol Physiol 1994; 21:73-81.
6. Zhang D, Meyron-Holtz E, Rouault TA. Renal iron metabolism: trans-ferrin iron delivery and the role of iron regulatory proteins. J Am Soc Nephrol 2007; 18:401-406.
7. Abouhamed M, Gburek J, Liu W, Torchalski B, Wilhelm A, Wolff NA, et al. Divalent metal transporter 1 in the kidney proximal tubule is expressed in late endosomes/lysosomal membranes: implications for renal handling of protein-metal complexes. Am J Physiol Renal Physiol 2006; 290:F1525-F1533.
8. Wareing M, Ferguson CJ, Delannoy M, Cox AG, McMahon RF, Green R, et al. Altered dietary iron intake is a strong modulator of renal DMT1 expression. Am J Physiol Renal Physiol 2003; 285:F1050-F1059.
9. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, et al. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 2001; 276:38911-38920.
10. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345:925-926.
11. Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T. Adaptive response of the heart to long term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009; 296:H585-H593.
12. Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 2003; 14:2466-2474.
13. Naito Y, Tsujino T, Fujioka Y, Ohyanagi M, Iwasaki T. Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats. Hypertension 2002; 40:827-833.
14. Naito Y, Hirotani S, Sawada H, Akahori H, Tsujino T, Masuyama T. Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension 2011; 57:497-504.
15. Pillebout E, Weitzman JB, Burtin M, Martino C, Federici P, Yaniv M, et al. JunD protects against chronic kidney disease by regulating paracrine mitogens. J Clin Invest 2003; 112:843-852.
16. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, et al. Activated protein C protects against diabetic nephr-opathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13:1349-1358.
17. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14:1370-1376.
18. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007; 50:877-883.
19. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011; 121:3233-3243.
20. Remuzzi A, Puntorieri S, Brugnetti B, Bertani T, Remuzzi G. Renopro-tective effect of low iron diet and its consequence on glomerular hemodynamics. Kidney Int 1991; 39:647-652.
21. Alfrey AC, Froment DH, Hammond WS. Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 1989; 36:753-759.
22. Nankivell BJ, Harris DC. Iron depletion in the remnant kidney. Nephron 1995; 70:340-347.
23. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-2084.
24. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.